Literature DB >> 31612514

Mortality after lung transplantation: a single-centre cohort analysis.

Jo Raskin1, Arno Vanstapel2,3, Eric K Verbeken3, Hanne Beeckmans1, Bart M Vanaudenaerde2, Stijn E Verleden2, Arne P Neyrinck4, Laurens J Ceulemans2,5, Dirk E Van Raemdonck2,5, Geert M Verleden1,2, Robin Vos1,2.   

Abstract

Detailed data on postoperative death in lung transplant (LTx) recipients are lacking. Therefore, we investigated all deaths after LTx in a large, single-centre, 25-year follow-up cohort. Prevalence, time, place and cause of death (COD) were retrospectively analysed for all patients undergoing primary LTx between July 1991 and December 2015 in our centre. Over subsequent years, postoperative survival significantly improved, with proportionally more patients surviving to 1-year post-LTx (P < 0.0001). A total of 347 (38.9%) LTx recipients died, of which 53.6% expired within 3 years post-LTx [median time to death 910 (236-2447) days]. Autopsy was performed in 34.8% of deaths. COD included CLAD in 27.1% (BOS 63.8% vs. RAS 36.2%); infection (26.5%); malignancy (15.6%); postoperative complication (11.2%); cardiovascular disease (4.6%) or other causes (6.9%). In 8.1%, no clear COD could be determined. COD significantly differed between the various LTx indications (P = 0.047). With longer follow-up, infection becomes a less prevalent COD, but CLAD and malignancies a more important COD. The majority of patients died on the intensive care unit (40.6%) or hospital ward (29.1%), but place of death varied depending on the underlying COD. The current study provides insights into the postoperative deaths of LTx recipients.
© 2019 Steunstichting ESOT.

Entities:  

Keywords:  cancer; chronic lung allograft dysfunction; lung transplantation; malignancy; mortality; outcome

Year:  2019        PMID: 31612514     DOI: 10.1111/tri.13540

Source DB:  PubMed          Journal:  Transpl Int        ISSN: 0934-0874            Impact factor:   3.782


  5 in total

Review 1.  The role of radiology in addressing the challenge of lung cancer after lung transplantation.

Authors:  Francis T Delaney; John G Murray; Barry D Hutchinson; Jim J Egan; Michelle Murray; Sara Winward; Nicola Ronan; Carmel G Cronin
Journal:  Eur Radiol       Date:  2022-06-16       Impact factor: 5.315

2.  Death after lung transplantation: improving long term survival despite perilous early postoperative years.

Authors:  Michiel E Erasmus; Wim van der Bij
Journal:  Transpl Int       Date:  2020-02       Impact factor: 3.782

3.  Optimization of Early Antimicrobial Strategies for Lung Transplant Recipients Based on Metagenomic Next-Generation Sequencing.

Authors:  Xiao-Qin Zhang; Yu Lei; Xiao-Li Tan; Lu Guo; Xiao-Bo Huang; Fu-Xun Yang; Hua Yu; Xiao-Shu Liu; Yi-Ping Wang; Sen Lu; Ling-Ai Pan
Journal:  Front Microbiol       Date:  2022-03-23       Impact factor: 5.640

4.  Outcome and prognostic factors after lung transplantation for bronchiectasis other than cystic fibrosis.

Authors:  Takashi Hirama; Fumiko Tomiyama; Hirotsugu Notsuda; Tatsuaki Watanabe; Yui Watanabe; Hisashi Oishi; Yoshinori Okada
Journal:  BMC Pulm Med       Date:  2021-08-13       Impact factor: 3.317

5.  Case Report: An Unusual Course of Angiosarcoma After Lung Transplantation.

Authors:  Saskia Bos; Liesbeth Daniëls; Lucienne Michaux; Isabelle Vanden Bempt; Sascha Vermeer; F J Sherida H Woei-A-Jin; Patrick Schöffski; Birgit Weynand; Raf Sciot; Sabine Declercq; Laurens J Ceulemans; Laurent Godinas; Geert M Verleden; Dirk E Van Raemdonck; Lieven J Dupont; Robin Vos
Journal:  Front Immunol       Date:  2022-01-03       Impact factor: 8.786

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.